Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adventa BhdXKLS:7191 32 3-Year EBITDA Growth Rate is 13.70% as of Mar. 2026. GuruFocus rates XKLS:7191 with a GF Score™ of 32/100 and a GF Value™ of RM0.24 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Adventa Bhd ranks better than 56.44% on this metric.
During the past 12 months, Adventa Bhd's average EBITDA Per Share Growth Rate was -180.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 13.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Adventa Bhd was 35.80% per year. The lowest was -57.20% per year. And the median was -2.65% per year.
Adventa Bhd (XKLS:7191) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Adventa Bhd 3-Year EBITDA Growth Rate Related Terms
XKLS:7191 vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Adventa Bhd's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adventa Bhd 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Adventa Bhd's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Adventa Bhd's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 13.70% mean?
Adventa Bhd (XKLS:7191) has a 3-Year EBITDA Growth Rate of 13.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Adventa Bhd and its competitors. According to the industry distribution chart, Adventa Bhd ranks #301 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 43.6%.
Is Adventa Bhd's 3-Year EBITDA Growth Rate too high?
Adventa Bhd's current 3-Year EBITDA Growth Rate is 13.70%. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.30. Adventa Bhd's value of 13.70% is 65.1% above this industry median. Based on the distribution chart, Adventa Bhd ranks #301 out of 691 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Adventa Bhd has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adventa Bhd's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Adventa Bhd ranks #301 out of 691 companies for 3-Year EBITDA Growth Rate. This puts Adventa Bhd in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.30. Adventa Bhd's value of 13.70% is 65.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.30, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adventa Bhd's current 3-Year EBITDA Growth Rate of 13.70% is 65.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Adventa Bhd and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adventa Bhd's current 3-Year EBITDA Growth Rate is 13.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adventa Bhd stock overvalued right now?
Based on GuruFocus' analysis, Adventa Bhd (XKLS:7191) is currently considered Possible Value Trap. The stock's GF Value™ is RM0.24, compared to a current price of RM0.14 — trading 43.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 13.70% and 65.1% above the Medical Devices & Instruments industry median of 8.30. Adventa Bhd's overall GF Score™ is 32/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Adventa Bhd (XKLS:7191), the current 3-Year EBITDA Growth Rate is 13.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adventa Bhd (XKLS:7191) Overvalued in 2026?
Based on GuruFocus' analysis, Adventa Bhd stock appears to be undervalued.
The current stock price of RM0.14 is trading 43.8% below its estimated GF Value™ of RM0.24.
GuruFocus considers Adventa Bhd to be Possible Value Trap.
Key valuation signals for XKLS:7191:
3-Year EBITDA Growth Rate: 13.70%
GF Value™: RM0.24 vs. price of RM0.14 (43.8% below fair value)
Industry Position: 65.1% above the Medical Devices & Instruments median (#301 of 691)
No single metric tells the full story. See the XKLS:7191 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adventa Bhd is engaged in investment holdings, management services, warehousing services, and the manufacturing, distribution, and supply of medical and healthcare equipment, appliances, and medical disposal products. It operates as a regional healthcare group focused on medical innovation, manufacturing excellence, and patient-centered solutions. Its segments include Investment Holdings, which involves investment in companies; Healthcare Products, which involves the manufacturing and supply of healthcare-related products and services to hospitals, healthcare centres, and pharmacies and generates maximum revenue; and Warehousing Provider, which provides storage and warehousing services. The company generates maximum revenue from Malaysia, followed by Indonesia and other countries.
32GF Score
Get the complete analysis for XKLS:7191
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7191 has been successfully added to your 
